Kisspeptins to Predict and Treat Delayed Puberty
AssigneesThe General Hospital Corporation, Children’s Medical Center Corporation
InventorsStephanie Beth Seminara, Yee-Ming Chan, Margaret Flynn Lippincott
Life of this patent
Estimating the term…
Abstract
Methods of diagnosing and treating pathologic hypogonadotropic hypogonadism and reproductive endocrine dysfunction using kisspeptin and kisspeptin analogs.
Claims22
A method of treating a subject who has a reproductive endocrine dysfunction, optionally pathologic hypogonadotropic hypogonadotropism, the method comprising administering a therapeutically effective amount of (i) a plurality of doses of kisspeptin or a kisspeptin analog, and/or (ii) an opioid antagonist or mixed agonist-antagonist to the subject.
A method of identifying a subject as having pathologic hypogonadotropic hypogonadotropism, being at risk for pathologic hypogonadotropic hypogonadism, or having an attenuated form of pathologic hypogonadotropic hypogonadism, the method comprising:
- measuring a baseline level of LH in the subject;
- administering a stimulating dose of kisspeptin or a kisspeptin analog to the subject, optionally a dose comprising to 0.08-15 nmol/kg kisspeptin-10, administered via intravenous bolus (IVB) or a dose comprising 0.8-500 nmol/kg kisspeptin-10, administered via subcutaneous (SC) injection;
- measuring at least one level of LH after administration of the stimulating dose;
- comparing the baseline level of LH in the subject to the level of LH after administration of the stimulating dose, and
- identifying a subject with delayed puberty who has a level of LH after administration of the stimulating dose that is not significantly different from the baseline level of LH as having pathologic hypogonadotropic hypogonadotropism.
-32. (canceled)
Dependencies are inferred from the claim text.